Johnson & Johnson (NYSE:JNJ) Shares Acquired by Woodmont Investment Counsel LLC

Woodmont Investment Counsel LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 0.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 85,671 shares of the company’s stock after purchasing an additional 625 shares during the period. Johnson & Johnson comprises about 1.0% of Woodmont Investment Counsel LLC’s holdings, making the stock its 23rd largest holding. Woodmont Investment Counsel LLC’s holdings in Johnson & Johnson were worth $13,884,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Johnson & Johnson during the 1st quarter worth about $765,000. Financial Counselors Inc. lifted its stake in Johnson & Johnson by 14.3% during the first quarter. Financial Counselors Inc. now owns 183,373 shares of the company’s stock worth $29,008,000 after purchasing an additional 22,943 shares during the last quarter. Blume Capital Management Inc. increased its stake in Johnson & Johnson by 2.6% in the first quarter. Blume Capital Management Inc. now owns 59,265 shares of the company’s stock valued at $9,375,000 after purchasing an additional 1,500 shares during the last quarter. Pegasus Asset Management Inc. raised its holdings in Johnson & Johnson by 2.6% during the first quarter. Pegasus Asset Management Inc. now owns 28,165 shares of the company’s stock worth $4,455,000 after purchasing an additional 725 shares in the last quarter. Finally, Smart Money Group LLC lifted its position in shares of Johnson & Johnson by 31.3% during the 1st quarter. Smart Money Group LLC now owns 5,074 shares of the company’s stock worth $734,000 after buying an additional 1,209 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $156.71 on Friday. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $168.85. The company has a 50-day moving average price of $162.96 and a 200 day moving average price of $155.76. The company has a market cap of $377.30 billion, a P/E ratio of 22.68, a PEG ratio of 2.81 and a beta of 0.53. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the previous year, the business earned $2.66 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. Research analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. Guggenheim increased their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday. Daiwa America cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 16th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Finally, Sanford C. Bernstein increased their price objective on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $175.00.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.